Vancomycin resistance in Gram-positive bacteria other than Enterococcus spp

Area of Science:

• Microbiology
• Infectious Diseases
• Antimicrobial Resistance

Background:

• Vancomycin is a critical antibiotic for treating serious Gram-positive infections.
• Increasing vancomycin resistance in bacteria poses a significant global health threat.
• Non-enterococcal Gram-positive bacteria are emerging as important reservoirs of vancomycin resistance.

Purpose of the Study:

• To review the current understanding of vancomycin resistance in Gram-positive bacteria, excluding enterococci.
• To discuss the epidemiological trends and clinical significance of vancomycin-resistant Listeria spp., Corynebacteria, streptococci, and staphylococci.
• To explore available and emerging therapeutic options for infections caused by these resistant pathogens.

Main Methods:

• Literature review of peer-reviewed articles and clinical studies.
• Analysis of epidemiological data on vancomycin resistance prevalence.
• Synthesis of information on clinical case reports and treatment outcomes.

Main Results:

• Vancomycin resistance is documented in various clinically relevant Gram-positive bacteria beyond enterococci.
• The prevalence and patterns of resistance vary geographically and by species.
• Treatment of infections caused by these resistant organisms presents significant challenges, often requiring alternative antibiotics or combination therapies.

Conclusions:

• Vancomycin resistance in non-enterococcal Gram-positive bacteria is a growing concern requiring vigilant monitoring.
• Effective management necessitates understanding resistance mechanisms, epidemiological trends, and judicious use of alternative therapies.
• Further research into novel therapeutic strategies is crucial to combat these challenging infections.